Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.

BACKGROUND Plasminogen activator inhibitor-1 (PAI-1) is increased in kidneys of humans and animals with diabetic nephropathy and is associated with extracellular matrix (ECM) accumulation. PAI-1 may promote ECM buildup by preventing plasmin and matrix metalloproteinase (MMP) activation. However, the importance and mechanism of PAI-1 action in the pathogenesis of diabetic nephropathy is unknown. METHODS We investigated the effect of streptozotocin (STZ)-induced diabetes in wild-type (PAI-1(+/+)) mice and mice null for PAI-1 (PAI-1(-/-)). After 1 month of diabetes, animals were placed in metabolic cages for 24-hour urine collection. Total RNA was isolated from kidney cortex for reverse transcription-polymerase chain reaction (RT-PCR) and Northern blot analysis, and Western blots were quantitated from cortical protein. Primary mesangial cells were grown from Sprague-Dawley rats and used in signal transduction studies. RESULTS Urinary albumin excretion (UAE) in diabetic PAI-1(+/+) mice increased >threefold, but remained unchanged in PAI-1(-/-) mice. Transforming growth factor-beta (TGF-beta) and fibronectin message and protein levels were lower in diabetic PAI-1(-/-) vs. PAI-1(+/+) mice, suggesting that PAI-1 deficiency impaired TGF-beta expression despite diabetes. Indeed, recombinant PAI-1 directly stimulated TGF-beta message and protein via mitogen-activated protein kinase (MAPK) signal transduction in cultured mesangial cells. Urokinase plasminogen activator (uPA) inhibited this PAI-1 action in a dose-dependent manner. The inhibitory effect of antibody to uPA receptor (uPAR) on PAI-1-induced TGF-beta function suggested that uPAR mediated the cellular effect of PAI-1. CONCLUSION PAI-1 can regulate TGF-beta expression by binding to uPAR and activating the extracellular-regulated signal kinase (ERK)/MAPK pathway. Therefore, PAI-1 contributes to diabetic nephropathy by regulating TGF-beta and renal ECM production and may be a therapeutic target in diabetic nephropathy.

• Publication year

  2005

• Venue

  Kidney International

• Publication date

  2005-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/J.1523-1755.2005.00207.XPMID 15780082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.

  2004cited by this paper
• Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.

  2004cited by this paper
• Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor.

  2003cited by this paper
• Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

  2003cited by this paper
• Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice.

  2003cited by this paper
• Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions.

  2003cited by this paper
• A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

  2003cited by this paper
• Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− Mice

  2003cited by this paper
• Dipstick proteinuria: can it guide hypertension management?

  2002cited by this paper
• Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.

  2002cited by this paper
• Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy.

  2002cited by this paper
• Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.

  2001cited by this paper
• Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells

  2001cited by this paper
• Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.

  2001cited by this paper
• Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.

  2001cited by this paper
• PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.

  2001cited by this paper
• Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.

  2000cited by this paper
• Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion.

  2000cited by this paper
• Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-alpha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets.

  2000cited by this paper
• Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-α, TGF-β, bFGF and Vimentin) in cultured and transplanted rat islets

  2000cited by this paper
• Matrix metalloproteinase‐2 activation in human hepatic fibrosis regulation by cell‐matrix interactions

  1999cited by this paper
• Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients.

  1999cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper
• The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule.

  1998cited by this paper
• Binding of Urokinase-type Plasminogen Activator to Its Receptor in MCF-7 Cells Activates Extracellular Signal-regulated Kinase 1 and 2 Which Is Required for Increased Cellular Motility*

  1998influential reference
• Activation of the serine proteinase system in chronic kidney rejection.

  1998cited by this paper
• Sp1 Sites Mediate Activation of the Plasminogen Activator Inhibitor-1 Promoter by Glucose in Vascular Smooth Muscle Cells*

  1998cited by this paper
• Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2.

  1998cited by this paper
• Expression of Matrix Metalloproteinases during Rat Skin Wound Healing: Evidence that Membrane Type-1 Matrix Metalloproteinase Is a Stromal Activator of Pro-Gelatinase A

  1997cited by this paper
• Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.

  1996cited by this paper
• Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents

  1996cited by this paper
• Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

  1996cited by this paper
• Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.

  1996cited by this paper
• Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate.

  1996cited by this paper
• Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP).

  1996cited by this paper
• Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney

  1996cited by this paper
• Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

  1995cited by this paper
• A noninvasive computerized tail-cuff system for measuring blood pressure in mice.

  1995cited by this paper
• ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.

  1995cited by this paper
• High Glucose Concentration Causes a Decrease in Mesangium Degradation: A Factor in the Pathogenesis of Diabetic Nephropathy

  1994influential reference
• Plasminogen activator inhibitor 1 activity and lipoprotein(a) in nephropathic patients with non-insulin-dependent diabetes mellitus versus patients with nondiabetic nephropathy.

  1994cited by this paper
• Regulation of PAI-1 Gene Expression In Vivo

  1993influential reference
• Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.

  1993cited by this paper
• The extracellular matrix in diabetic nephropathy.

  1993cited by this paper
• Glomerular matrix accumulation is linked to inhibition of the plasmin protease system.

  1992cited by this paper
• Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.

  1992cited by this paper
• Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.

  1992cited by this paper
• Proteolytic enzymes as mediators of glomerular injury.

  1991cited by this paper
• Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor

  1991cited by this paper
• A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.

  1991cited by this paper
• Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.

  1989cited by this paper
• Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts.

  1989cited by this paper
• Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus

  1988cited by this paper
• Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts.

  1987cited by this paper
• Enhanced production and extracellular deposition of the endothelial- type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta

  1986cited by this paper
• Structural-functional relationships in diabetic nephropathy.

  1984cited by this paper

• Involvement of c-Myc/WWP1/TRIM65 Axis in Renal Fibrosis

  2026cites this paper
• Post-translational modifications in diabetic kidney disease (Review)

  2026cites this paper
• Synergy of zinc oxide nanoparticles to losartan attenuates kidney injury induced by unilateral ureteral obstruction through modulation of the TNF-α/IL6 and BAX/BCL2 signaling pathways

  2025cites this paper
• Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases

  2025cites this paper
• Pathogenesis of diabetic complications: Exploring hypoxic niche formation and HIF-1α activation.

  2024cites this paper
• Serpin E1 mediates the induction of renal tubular degeneration and premature senescence upon diabetic insult

  2023cites this paper
• Arid5a/IL-6/PAI-1 Signaling Is Involved in the Pathogenesis of Lipopolysaccharide-Induced Kidney Injury.

  2023cites this paper
• Modeling SILAC Data to Assess Protein Turnover in a Cellular Model of Diabetic Nephropathy

  2023cites this paper
• Pathomechanisms of Diabetic Kidney Disease

  2023cites this paper
• The Role of Histone Modifications in the Pathogenesis of Diabetic Kidney Disease

  2023cites this paper
• Plasmacytoma Variant Translocation 1 (PVT1) Gene as a Potential Novel Target for the Treatment of Diabetic Nephropathy

  2022cites this paper
• Immune-related SERPINA3 as a biomarker involved in diabetic nephropathy renal tubular injury

  2022cites this paper
• The Perspective of Vitamin D on suPAR-Related AKI in COVID-19

  2022cites this paper
• Vitamin D3 Repletion Improves Vascular Function, as Measured by Cardiorenal Biomarkers in a High-Risk African American Cohort

  2022cites this paper
• The Astragaloside IV Derivative LS-102 Ameliorates Obesity-Related Nephropathy

  2022cites this paper
• Anti-fibrotic effect of 6-bromo-indirubin-3'-oxime (6-BIO) via regulation of activator protein-1 (AP-1) and specificity protein-1 (SP-1) transcription factors in kidney cells.

  2021cites this paper
• PAI‐1 induction during kidney injury promotes fibrotic epithelial dysfunction via deregulation of klotho, p53, and TGF‐β1‐receptor signaling

  2021cites this paper
• The Genomic Response to TGF-β1 Dictates Failed Repair and Progression of Fibrotic Disease in the Obstructed Kidney

  2021cites this paper
• Cellular senescence and the senescence-associated secretory phenotype: Potential therapeutic targets for renal fibrosis.

  2021cites this paper
• GYY4137 Regulates Extracellular Matrix Turnover in the Diabetic Kidney by Modulating Retinoid X Receptor Signaling

  2021cites this paper
• PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

  2021cites this paper
• Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control

  2020cites this paper
• MG53 Does Not Manifest the Development of Diabetes in db/db Mice

  2020cites this paper
• The Microbiome Product Urolithin A Abrogates the TGF-ò-EGFR-PAI-1 Pathway in NRK-52e Renal Epithelial Cells

  2020cites this paper
• Role of Senescent Renal Cells in Pathophysiology of Diabetic Kidney Disease

  2020cites this paper
• Targeting the progression of chronic kidney disease

  2020cites this paper
• Impaired ECM Remodeling and Macrophage Activity Define Necrosis and Regeneration Following Damage in Aged Skeletal Muscle

  2020cites this paper
• Association of plasminogen activator inhibitor-1 4G5G Polymorphism with risk of diabetic nephropathy and retinopathy: a systematic review and meta-analysis

  2020cites this paper
• Molecular biomarkers of Graves' ophthalmopathy.

  2019cites this paper
• Gender difference in plasminogen activator inhibitor-1 activity in patients with type 2 diabetes with and without albuminuria, a matched case-control study

  2019cites this paper
• Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction.

  2019cites this paper
• Inhibition of PAI-1 attenuates perirenal fat inflammation and the associated nephropathy in high-fat diet-induced obese mice.

  2019cites this paper
• Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis

  2018cites this paper
• Coagulation and Hemostasis in Diabetic Nephropathy

  2018cites this paper
• 3 Chapter 3 Protease activated receptor 2 in diabetic nephropathy : a double edged sword .

  2018cites this paper
• TGF-β1/p53 signaling in renal fibrogenesis.

  2018cites this paper
• PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI - 1) AS A POTENTIAL DIAGNOSTIC AND THERAPEUTIC TARGET

  2018cites this paper
• Herba Artemisiae Capillaris Extract Prevents the Development of Streptozotocin-Induced Diabetic Nephropathy of Rat

  2018influential citation
• Susceptible and Prognostic Genetic Factors Associated with Diabetic Peripheral Neuropathy: A Comprehensive Literature Review

  2018cites this paper
• Protease activated receptor 2 in diabetic nephropathy: a double edged sword.

  2017cites this paper
• ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice

  2017cites this paper
• Physiology and pathophysiology of the plasminogen system in the kidney

  2017cites this paper
• Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies

  2016cites this paper
• Effects of Bone Marrow Mesenchymal Stem Cells on Plasminogen Activator Inhibitor-1 and Renal Fibrosis in Rats with Diabetic Nephropathy.

  2016cites this paper
• An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.

  2016cites this paper
• Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-β-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts

  2016cites this paper
• The emerging role of coagulation proteases in kidney disease

  2016cites this paper
• Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model

  2016cites this paper
• Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation.

  2016cites this paper
• Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy

  2016cites this paper
• Inhibition of PAI-1 Via PAI-039 Improves Dermal Wound Closure in Diabetes

  2015cites this paper
• Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.

  2015cites this paper
• Hyperglycemia-suppressed expression of Serpine1 contributes to delayed epithelial wound healing in diabetic mouse corneas.

  2015cites this paper
• Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy.

  2014cites this paper
• A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes

  2014influential citation
• Effects of uPA on mesangial matrix changes in the kidney of diabetic rats

  2014cites this paper
• Wnt/β-catenin signaling and kidney fibrosis

  2014cites this paper
• Involvement of p300/CBP and epigenetic histone acetylation in TGF-β1-mediated gene transcription in mesangial cells.

  2013influential citation
• An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion.

  2013cites this paper
• Gender-specific role of HDAC11 in kidney ischemia- and reperfusion-induced PAI-1 expression and injury.

  2013cites this paper
• Plasminogen activator inhibitor-1 in kidney pathology (Review).

  2013cites this paper
• Ubiquitin‐specific protease 2‐69 in macrophages potentially modulates metainflammation

  2013cites this paper
• Analysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products.

  2013cites this paper
• Clusterin attenuates the development of renal fibrosis.

  2012cites this paper
• Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes

  2012cites this paper
• Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1.

  2012cites this paper
• Glibenclamide Induces Collagen IV Catabolism in High Glucose-Stimulated Mesangial Cells

  2012cites this paper
• Can drinking black tea fight diabetes: literature review and theoretical indication

  2012cites this paper
• DIABeTIC NePhROPAThy : NOvel meChANISmS AND TheRAPIeS IN 2010

  2012cites this paper
• The role of matrix metalloproteinases and their inhibitors in the development of renal fibrosis in the patients with diabetes mellitus

  2012cites this paper
• New era for drug discovery and development in renal disease

  2011cites this paper
• Inhibition of Plasminogen Activator Inhibitor-1 Restores Skeletal Muscle Regeneration in Untreated Type 1 Diabetic Mice

  2011cites this paper
• Bench-to-bedside review: Ventilation-induced renal injury through systemic mediator release - just theory or a causal relationship?

  2011cites this paper
• TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis

  2011cites this paper
• Amelioration of glomerulosclerosis with all-trans retinoic acid is linked to decreased plasminogen activator inhibitor-1 and α-smooth muscle actin

  2011cites this paper
• Novel Drug Treatment for Diabetic Nephropathy

  2011cites this paper
• Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review).

  2011cites this paper
• Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage

  2011cites this paper
• Glucocorticoid enhances hypoxia- and/or transforming growth factor-β-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells

  2011cites this paper
• Targeted therapies in diabetic nephropathy: an update.

  2011cites this paper
• The identification of gene expression profiles associated with progression of human diabetic neuropathy.

  2011cites this paper
• Triptolide inhibits extracellular matrix protein synthesis by suppressing the Smad2 but not the MAPK pathway in TGF-beta1-stimulated NRK-49F cells.

  2010cites this paper
• Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors.

  2010cites this paper
• Plasminogen Activator Inhibitor-1 Is a Transcriptional Target of the Canonical Pathway of Wnt/β-Catenin Signaling*

  2010cites this paper
• A Novel Inhibitor of Plasminogen Activator Inhibitor-1 Provides Antithrombotic Benefits Devoid of Bleeding Effect in Nonhuman Primates

  2010cites this paper
• Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice

  2010cites this paper
• Combating Combination of Hypertension and Diabetes in Different Rat Models

  2010cites this paper
• Integration of text mining with systems biology provides new insight into the pathogenesis of diabetic neuropathy

  2010cites this paper
• New pharmacological treatments for improving renal outcomes in diabetes

  2010cites this paper
• Plasminogen activator inhibitor-1 antisense oligodeoxynucleotides abrogate mesangial fibronectin accumulation.

  2010cites this paper
• EXPRESSION PROFILING OF BLOOD VESSELS IN PERICYTE DEFICIENCY AND DIABETES

  2010cites this paper
• Deletion of the Receptor for Advanced Glycation End Products Reduces Glomerulosclerosis and Preserves Renal Function in the Diabetic OVE26 Mouse

  2010cites this paper
• Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors

  2010cites this paper
• Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice

  2010cites this paper
• Dexamethasone enhances basal and TNF-alpha-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11beta-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells.

  2009cites this paper
• Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis.

  2009cites this paper
• Translation of basic science into clinical medicine: novel targets for diabetic nephropathy.

  2009cites this paper
• Transforming growth factor in diabetes and renal disease

  2009cites this paper
• Transcription factors in the pathogenesis of diabetic nephropathy

  2009cites this paper
• Histological assessment of the possible protective role of glimepiride against progression of experimentally induced diabetic nephropathy in rats

  2009cites this paper